meRfi®-GM
Intestine GVHD
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Broad-spectrum antibiotics (ATB) such as carbapenems increase the risk of intestinal GVHD
The carbapenem meropenem exacerbates colonic GvHD in mice via expansion of Bacteroides thetaiotaomicron (BT)
Patients with Intestine GVHD refractory to treatment with glucocorticosteroids, c…
References (Sources)
- First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation
- Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease
- Mucus-degrading Bacteroides link carbapenems to aggravated graft-versushost disease
- Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation
- Steroid-refractory acute GVHD: predictors and outcomes
- The primacy of the gastrointestinal tract as a target organ of acute graft-versus host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation
- The Role of Fecal Microbiota Transplantation in the Treatment of Acute Graft-versus-Host Disease